{
  "docId": "019dd923-622c-750b-8b99-62a16d2a2f71",
  "docSlug": "747988e81365",
  "documentTitle": "Hims & Hers Health, Inc. (HIMS)",
  "authorId": "54_Spruce_Point_Capital",
  "authorName": "Spruce Point Capital Management",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2023-07-13 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 11,
  "pageCount": 105,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "key_messages",
  "function": "diagnose_problem",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide uses a two-section structure to categorize risks: supply chain/operational risks and competitive/market positioning risks.",
  "elementsJson": [
    "headline_text",
    "bullet_list",
    "paragraph"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b99-62a16d2a2f71/11",
  "deckHref": "/decks/019dd923-622c-750b-8b99-62a16d2a2f71",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b99-62a16d2a2f71.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b99-62a16d2a2f71#slide-11",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "We believe HIMS is exposed to material operational and reputational risks from the third-party pharmacies that comprise nearly 50% of its current pharmacy supply chain.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-0f1d-76e6-8702-33905e9115bc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.95,
        "x": 0.03,
        "y": 0.21
      },
      "kind": "list",
      "text": "Pharmacy fulfillment provider Truepill potentially faces existential risk from an ongoing Drug Enforcement Agency (DEA) investigation... An FDA inspection of HIMS supplier ITC Compounding uncovered such severe violations... Although HIMS has attempted to move more production in-house...",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "119b30c0-19eb-4294-b1aa-9675857a27de",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.42,
        "w": 0.95,
        "x": 0.03,
        "y": 0.52
      },
      "kind": "list",
      "text": "HIMS has made its name selling completely commoditized generic medications at massive premiums... direct competitors Ro Health and Keeps... have strong mindshare... broad based players like Mark Cuban's Cost Plus Drug Company are growing rapidly... HIMS has a reputation as the high-priced supplier... recent FDA approval of Eroxon... former HIMS employees and physicians admitted to us that the Company's products are commoditized and overpriced",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4be25eda-f012-4643-a721-a293ed7c53e6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.95,
        "x": 0.03,
        "y": 0.16
      },
      "kind": "paragraph",
      "text": "We believe HIMS is exposed to material operational and reputational risks from the third-party pharmacies that comprise nearly 50% of its current pharmacy supply chain.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a038f316-51a0-4642-9ba6-5aaa6ea96799",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.95,
        "x": 0.03,
        "y": 0.47
      },
      "kind": "paragraph",
      "text": "We believe that HIMS, as a seller of commoditized prescription and OTC treatments, has little sustainable competitive advantage and is poorly positioned for the entry of OTC ED medications and new competitors into the online pharmacy market.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bd63ec5d-79d0-4aec-b955-0a2ef4211d3c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.7,
        "x": 0.28,
        "y": 0.03
      },
      "kind": "title",
      "text": "HIMS' Supply Chain Is At Risk And The Company Is Poorly Positioned For An Increasingly Competitive Market",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8ac1d8ac-fa41-4dce-81cd-8f25367a65a2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 13,
      "from": 9,
      "beatId": "222268c8-de44-43e0-b3f6-65160180d040",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "Complication",
      "beatSlug": "complication",
      "evidence": "The document presents several complications with HIMS' business model, including operational structure and supply chain risks",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    },
    {
      "to": 53,
      "from": 4,
      "beatId": "80bd0218-c4cf-4186-b917-bf58199ab190",
      "arcName": "Overcoming the Monster",
      "arcSlug": "overcoming-monster",
      "beatName": "Villain Critique",
      "beatSlug": null,
      "evidence": "The document presents a thorough critique of HIMS, framing it as a villain in the healthcare market",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}